Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00950300




Registration number
NCT00950300
Ethics application status
Date submitted
30/07/2009
Date registered
31/07/2009
Date last updated
23/01/2018

Titles & IDs
Public title
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Scientific title
A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-Positive Early Breast Cancer (EBC)
Secondary ID [1] 0 0
2008-007326-19
Secondary ID [2] 0 0
BO22227
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - 5-Fluorouracil
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Docetaxel
Treatment: Drugs - Epirubicin
Treatment: Drugs - Herceptin IV [trastuzumab]
Treatment: Drugs - Herceptin SC [trastuzumab]

Active Comparator: Herceptin IV + Chemotherapy - Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.

Experimental: Herceptin SC + Chemotherapy - Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.


Treatment: Drugs: 5-Fluorouracil
Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Treatment: Drugs: Cyclophosphamide
Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Treatment: Drugs: Docetaxel
Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.

Treatment: Drugs: Epirubicin
Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.

Treatment: Drugs: Herceptin IV [trastuzumab]
Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.

Treatment: Drugs: Herceptin SC [trastuzumab]
Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery
Timepoint [1] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Primary outcome [2] 0 0
Percentage of Participants With Pathological Complete Response (pCR)
Timepoint [2] 0 0
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Secondary outcome [1] 0 0
Observed Ctrough of Trastuzumab After Surgery
Timepoint [1] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [2] 0 0
Predicted Ctrough of Trastuzumab Prior to Surgery
Timepoint [2] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Secondary outcome [3] 0 0
Predicted Ctrough of Trastuzumab After Surgery
Timepoint [3] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [4] 0 0
Number of Participants With Ctrough of Trastuzumab >20 µg/mL Prior to Surgery
Timepoint [4] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Secondary outcome [5] 0 0
Number of Participants With Ctrough of Trastuzumab >20 µg/mL After Surgery
Timepoint [5] 0 0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [6] 0 0
Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery
Timepoint [6] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Secondary outcome [7] 0 0
Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery
Timepoint [7] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Secondary outcome [8] 0 0
Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery
Timepoint [8] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Secondary outcome [9] 0 0
Cmax of Trastuzumab After Surgery
Timepoint [9] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [10] 0 0
Tmax of Trastuzumab After Surgery
Timepoint [10] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [11] 0 0
AUC21d of Trastuzumab After Surgery
Timepoint [11] 0 0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Secondary outcome [12] 0 0
Percentage of Participants With Total Pathological Complete Response (tpCR)
Timepoint [12] 0 0
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Secondary outcome [13] 0 0
Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline
Timepoint [13] 0 0
Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)
Secondary outcome [14] 0 0
Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline
Timepoint [14] 0 0
Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)
Secondary outcome [15] 0 0
Percentage of Participants Who Experienced a Protocol-Defined Event
Timepoint [15] 0 0
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Secondary outcome [16] 0 0
Event-Free Survival (EFS)
Timepoint [16] 0 0
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Secondary outcome [17] 0 0
Percentage of Participants Who Died
Timepoint [17] 0 0
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Secondary outcome [18] 0 0
Overall Survival (OS)
Timepoint [18] 0 0
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Secondary outcome [19] 0 0
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab
Timepoint [19] 0 0
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Secondary outcome [20] 0 0
Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)
Timepoint [20] 0 0
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18

Eligibility
Key inclusion criteria
* Adult women greater than or equal to (=) 18 years of age
* Non-metastatic primary invasive adenocarcinoma of the breast clinical stage I to IIIC, including inflammatory and multicentric/multifocal breast cancer, with tumor size =1 centimeter (cm) by ultrasound or =2 cm by palpation, centrally confirmed HER2-positive (immunohistochemical score [IHC] 3+ or in situ hybridization [ISH]-positive)
* At least 1 measurable lesion in breast or lymph nodes (=1 cm by ultrasound or =2 cm by palpation), except for inflammatory carcinoma (T4d)
* Baseline left ventricular ejection fraction (LVEF) =55%
* Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
* Adequate organ function at Baseline
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma
* Past or current history of malignant neoplasms, except for curatively treated basal and squamous cell carcinoma of the skin and in situ carcinoma of the cervix
* Metastatic disease
* Any prior therapy with anthracyclines
* Prior anti-HER2 therapy or biologic or immunotherapy
* Serious cardiac illness
* Pregnant or lactating women

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/10/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/01/2017
Sample size
Target
Accrual to date
Final
596
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Tucuman
Country [2] 0 0
Brazil
State/province [2] 0 0
BA
Country [3] 0 0
Brazil
State/province [3] 0 0
PR
Country [4] 0 0
Brazil
State/province [4] 0 0
RN
Country [5] 0 0
Brazil
State/province [5] 0 0
SC
Country [6] 0 0
Brazil
State/province [6] 0 0
SP
Country [7] 0 0
Canada
State/province [7] 0 0
Quebec
Country [8] 0 0
Colombia
State/province [8] 0 0
Bogota
Country [9] 0 0
Colombia
State/province [9] 0 0
Pereira
Country [10] 0 0
Czechia
State/province [10] 0 0
Olomouc
Country [11] 0 0
Czechia
State/province [11] 0 0
Pardubice
Country [12] 0 0
Czechia
State/province [12] 0 0
Praha
Country [13] 0 0
Estonia
State/province [13] 0 0
Tallinn
Country [14] 0 0
Estonia
State/province [14] 0 0
Tartu
Country [15] 0 0
France
State/province [15] 0 0
Besancon
Country [16] 0 0
France
State/province [16] 0 0
Grenoble
Country [17] 0 0
France
State/province [17] 0 0
La Tronche
Country [18] 0 0
France
State/province [18] 0 0
Le Mans
Country [19] 0 0
France
State/province [19] 0 0
Paris
Country [20] 0 0
France
State/province [20] 0 0
Reims
Country [21] 0 0
France
State/province [21] 0 0
St Cloud
Country [22] 0 0
Germany
State/province [22] 0 0
Berlin
Country [23] 0 0
Germany
State/province [23] 0 0
Bonn
Country [24] 0 0
Germany
State/province [24] 0 0
Dortmund
Country [25] 0 0
Germany
State/province [25] 0 0
Hannover
Country [26] 0 0
Germany
State/province [26] 0 0
Leipzig
Country [27] 0 0
Germany
State/province [27] 0 0
Lemgo
Country [28] 0 0
Germany
State/province [28] 0 0
Offenbach
Country [29] 0 0
Germany
State/province [29] 0 0
Rodewisch
Country [30] 0 0
Germany
State/province [30] 0 0
Tübingen
Country [31] 0 0
Guatemala
State/province [31] 0 0
Guatemala
Country [32] 0 0
Hong Kong
State/province [32] 0 0
Hong Kong
Country [33] 0 0
Hungary
State/province [33] 0 0
Budapest
Country [34] 0 0
Hungary
State/province [34] 0 0
Gyor
Country [35] 0 0
Hungary
State/province [35] 0 0
Szeged
Country [36] 0 0
Israel
State/province [36] 0 0
Jerusalem
Country [37] 0 0
Israel
State/province [37] 0 0
Petach Tikva
Country [38] 0 0
Italy
State/province [38] 0 0
Campania
Country [39] 0 0
Italy
State/province [39] 0 0
Lombardia
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Incheon
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Seoul
Country [42] 0 0
Mexico
State/province [42] 0 0
Obregon
Country [43] 0 0
Mexico
State/province [43] 0 0
Toluca
Country [44] 0 0
Panama
State/province [44] 0 0
Panama
Country [45] 0 0
Peru
State/province [45] 0 0
Arequipa
Country [46] 0 0
Peru
State/province [46] 0 0
Lima
Country [47] 0 0
Peru
State/province [47] 0 0
Piura
Country [48] 0 0
Peru
State/province [48] 0 0
San Isidro
Country [49] 0 0
Poland
State/province [49] 0 0
Elblag
Country [50] 0 0
Poland
State/province [50] 0 0
Lublin
Country [51] 0 0
Poland
State/province [51] 0 0
Olsztyn
Country [52] 0 0
Poland
State/province [52] 0 0
Warszawa
Country [53] 0 0
Russian Federation
State/province [53] 0 0
Leningrad
Country [54] 0 0
Russian Federation
State/province [54] 0 0
Ivanovo
Country [55] 0 0
Russian Federation
State/province [55] 0 0
Moscow
Country [56] 0 0
Russian Federation
State/province [56] 0 0
Pyatigorsk
Country [57] 0 0
Russian Federation
State/province [57] 0 0
Ryazan
Country [58] 0 0
Russian Federation
State/province [58] 0 0
Samara
Country [59] 0 0
Russian Federation
State/province [59] 0 0
Saratov
Country [60] 0 0
Russian Federation
State/province [60] 0 0
St Petersburg
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Stavropol
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Tula
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Vladimir
Country [64] 0 0
Slovakia
State/province [64] 0 0
Kosice
Country [65] 0 0
Slovakia
State/province [65] 0 0
Poprad
Country [66] 0 0
South Africa
State/province [66] 0 0
Bloemfontein
Country [67] 0 0
South Africa
State/province [67] 0 0
Cape Town
Country [68] 0 0
South Africa
State/province [68] 0 0
Parktown, Johannesburg
Country [69] 0 0
South Africa
State/province [69] 0 0
Pretoria
Country [70] 0 0
South Africa
State/province [70] 0 0
Rondebosch
Country [71] 0 0
South Africa
State/province [71] 0 0
Sandton
Country [72] 0 0
Spain
State/province [72] 0 0
LA Coruña
Country [73] 0 0
Spain
State/province [73] 0 0
Tarragona
Country [74] 0 0
Spain
State/province [74] 0 0
Madrid
Country [75] 0 0
Spain
State/province [75] 0 0
Valencia
Country [76] 0 0
Spain
State/province [76] 0 0
Zaragoza
Country [77] 0 0
Sweden
State/province [77] 0 0
Lund
Country [78] 0 0
Sweden
State/province [78] 0 0
Uppsala
Country [79] 0 0
Taiwan
State/province [79] 0 0
Changhua
Country [80] 0 0
Taiwan
State/province [80] 0 0
Taipei City
Country [81] 0 0
Taiwan
State/province [81] 0 0
Taipei
Country [82] 0 0
Taiwan
State/province [82] 0 0
Taoyuan
Country [83] 0 0
Thailand
State/province [83] 0 0
Bangkok
Country [84] 0 0
Thailand
State/province [84] 0 0
Songkhla
Country [85] 0 0
Turkey
State/province [85] 0 0
Antalya
Country [86] 0 0
Turkey
State/province [86] 0 0
Istanbul
Country [87] 0 0
Turkey
State/province [87] 0 0
Izmir
Country [88] 0 0
Turkey
State/province [88] 0 0
Sihhiye, Ankara

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
In this open-label multicenter trial, participants with operable or locally advanced breast cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide) concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of treatment. All cycles will be 21 days in length. After the end of study treatment, participants will be followed for safety and efficacy for up to 5 years or until disease recurrence, whichever is earlier.
Trial website
https://clinicaltrials.gov/study/NCT00950300
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00950300